3-benzylpyrazin-2-ol | 57674-16-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-benzylpyrazin-2-ol
• 英文别名: 2-Benzyl-3-hydroxypyrazin；3-Benzylpyrazin-2(1H)-one；3-benzyl-1H-pyrazin-2-one
• CAS: 57674-16-5
• 化学式: C₁₁H₁₀N₂O
• 分子量: 186.213
• InChiKey: QDRCDZXQXLCJTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  草酸醛 、 alpha-氨基-苯丙酰胺 生成 3-benzylpyrazin-2-ol
  参考文献：
  名称：

  抗球虫药。V.2（1H）-吡嗪酮4-氧化物衍生物的合成和抗球虫活性。

  摘要：

  合成了一系列1-、3-、5-和6取代的2(1H)-吡咯啉酮4-氧化物，并测试其抗球虫活性。在测试的化合物中，1-(β-D-核糖苷)-(22)、1-(2, 3, 5-三-O-苯甲酰-β-D-核糖苷)-(21)和1-(2, 3, 5-三-O-乙酰-β-D-核糖苷)-2(1H)-吡咯啉酮4-氧化物(24)显示出较高的活性。

  DOI：

  10.1248/cpb.28.2734

文献信息

• Anticoccidials. V. Synthesis and anticoccidial activity of 2(1H)-pyrazinone 4-oxide derivatives.
  作者：MITSUHIKO MANO、TAKUJI SEO、TOSHINORI HATTORI、TATSUHIKO KANEKO、KINICHI IMAI

  DOI：10.1248/cpb.28.2734

  日期：——

  A series of 1-, 3-, 5- and 6-substituted 2(1H)-pyrazinone 4-oxides were synthesized and tested for anticoccidial activity. Of the compounds tested, 1-(β-D-ribofuranosyl)-(22), 1-(2, 3, 5-tri-O-benzoyl-β-D-ribofuranosyl)-(21) and 1-(2, 3, 5-tri-O-acetyl-β-D-ribofuranosyl)-2(1H)-pyrazinone 4-oxides (24) showed high activity.

  合成了一系列1-、3-、5-和6取代的2(1H)-吡咯啉酮4-氧化物，并测试其抗球虫活性。在测试的化合物中，1-(β-D-核糖苷)-(22)、1-(2, 3, 5-三-O-苯甲酰-β-D-核糖苷)-(21)和1-(2, 3, 5-三-O-乙酰-β-D-核糖苷)-2(1H)-吡咯啉酮4-氧化物(24)显示出较高的活性。
• Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor
  申请人：Nishimura Toshihiro

  公开号：US20050049203A1

  公开（公告）日：2005-03-03

  The present invention provides nitrogen-containing heterocyclic derivatives represented by the general formula: wherein X 1 and X 3 independently represent N or CH; X 2 represents N or CR 2 ; X 4 represents N or CR 3 ; and with the proviso that one or two of X 1 , X 2 , X 3 and X 4 represent N; R 1 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted(lower alkoxy) group, a lower alkoxy(lower alkoxy) -substituted (lower alkyl) group, a cyclic lower alkyl group, a halo(lower alkyl) group or a group represented by the general formula: HO-A—wherein A represents a lower alkylene group, a lower alkyleneoxy group or a lower alkylenethio group; R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, a cyclic lower alkyl group, a lower alkoxy group, an amino group, a (lower acyl)amino group, a mono(lower alkyl)amino group or a di(lower alkyl)amino group; and R 3 represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, or prodrugs thereof which are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutical compositions comprising the same, and pharmaceutical uses and production intermediates thereof.

  本发明提供了一种以通式表示的含氮杂环衍生物： 其中，X1和X3独立地表示N或CH；X2表示N或CR2；X4表示N或CR3；并且假定X1、X2、X3和X4中的一个或两个表示N；R1表示氢原子、卤素原子、低碳基、低烷氧基、低硫代烷基、低烷氧基取代的（低烷基）基团、低烷氧基取代的（低烷氧基）基团、低烷氧基（低烷氧基）取代的（低烷基）基团、环状低烷基、卤素（低烷基）基团或由通式HO-A-表示的基团，其中A表示低碳亚烷基、低碳亚烷氧基或低碳亚烷硫基；R2表示氢原子、卤素原子、低碳基、环状低碳基、低烷氧基、氨基、（低酰基）氨基、单（低烷基）氨基或双（低烷基）氨基；R3表示氢原子或低碳基，或其药学上可接受的盐，或其前药，其作为预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症的药剂，包括这些药剂的制剂和制备中间体。
• On Reuben G. Jones synthesis of 2-hydroxypyrazines
  作者：Pierre Legrand、Yves L Janin

  DOI：10.3762/bjoc.18.93

  日期：——

  In 1949, Reuben G. Jones disclosed an original synthesis of 2-hydroxypyrazines involving a double condensation between 1,2-dicarbonyls and α-aminoamides upon treatment with sodium hydroxide at low temperature. This discovery turned out to be of importance as even today there are no simple alternatives to this preparation. Across the years, it was employed to prepare 2-hydroxypyrazines but some of its

  1949 年，Reuben G. Jones 公开了 2-羟基吡嗪的原始合成，包括在低温下用氢氧化钠处理时，1,2-二羰基和 α-氨基酰胺之间的双重缩合。事实证明，这一发现很重要，因为即使在今天，这种制备方法也没有简单的替代方法。多年来，它被用于制备 2-羟基吡嗪，但它的一些局限性，特别是从 α-酮醛开始时的区域选择性问题，无疑阻碍了药物化学中具有潜在兴趣的含吡嗪新化学实体的成熟一代。本文描述了一些见解和改进，例如前所未有地使用氢氧化四烷基铵，在从苯基乙二醛和两个α-氨基酰胺开始时影响区域选择性和产率的反应参数中。我们还提出了一种机制来解释 3,5-取代-2-羟基吡嗪作为主要反应产物的反直觉发生。
• NITROGENOUS HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE THEREFOR
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1405859A1

  公开（公告）日：2004-04-07

  The present invention is to provide a nitrogen-containing heterocyclic derivative represented by the general formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof, which exerts an excellent inhibitory activity in human SGLT2 and is useful as an agent for the prevention or treatment of a disease associated with hyperglycemia such as diabetes etc., or a pharmaceutical composition comprising the same and a pharmaceutical use thereof and a production intermediate thereof. In the general formula (I), X1 and X3 are N or CH; X2 is N or CR2; X4 is N or CR3; and with the proviso that one or two of X1, X2, X3 and X4 are N; and R1, R2 and R3 are a hydrogen atom etc.

  本发明旨在提供一种由通式(I)代表的含氮杂环衍生物或其药学上可接受的盐，或其原药，该衍生物对人SGLT2具有优异的抑制活性，可作为预防或治疗糖尿病等与高血糖相关疾病的药物，或由其组成的药物组合物及其药物用途和其生产中间体。在通式（I）中，X1 和 X3 是 N 或 CH；X2 是 N 或 CR2；X4 是 N 或 CR3；但条件是 X1、X2、X3 和 X4 中的一个或两个是 N；R1、R2 和 R3 是氢原子等。
• Processes and host cells for genome, pathway, and biomolecular engineering
  申请人：enEvolv, Inc.

  公开号：US10370654B2

  公开（公告）日：2019-08-06

  The present disclosure provides compositions and methods for genomic engineering.

  本公开提供了基因组工程的组合物和方法。